DNLI
Price
$15.43
Change
+$0.64 (+4.33%)
Updated
Sep 5 closing price
Capitalization
2.16B
54 days until earnings call
TLPPF
Price
$9.04
Change
-$0.18 (-1.95%)
Updated
Sep 5 closing price
Capitalization
3.02B
Interact to see
Advertisement

DNLI vs TLPPF

Header iconDNLI vs TLPPF Comparison
Open Charts DNLI vs TLPPFBanner chart's image
Denali Therapeutics
Price$15.43
Change+$0.64 (+4.33%)
Volume$4.19M
Capitalization2.16B
Telix Pharmaceutical
Price$9.04
Change-$0.18 (-1.95%)
Volume$569
Capitalization3.02B
DNLI vs TLPPF Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLPPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. TLPPF commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and TLPPF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (DNLI: $15.43 vs. TLPPF: $9.04)
Brand notoriety: DNLI and TLPPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 245% vs. TLPPF: 7%
Market capitalization -- DNLI: $2.16B vs. TLPPF: $3.02B
DNLI [@Biotechnology] is valued at $2.16B. TLPPF’s [@Biotechnology] market capitalization is $3.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileTLPPF’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • TLPPF’s FA Score: 1 green, 4 red.
According to our system of comparison, TLPPF is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while TLPPF’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • TLPPF’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TLPPF is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +1.05% price change this week, while TLPPF (@Biotechnology) price change was -8.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLPPF($3.02B) has a higher market cap than DNLI($2.16B). DNLI YTD gains are higher at: -24.289 vs. TLPPF (-39.633). TLPPF has higher annual earnings (EBITDA): 92.5M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. TLPPF (710M). DNLI has less debt than TLPPF: DNLI (46.6M) vs TLPPF (581M). TLPPF has higher revenues than DNLI: TLPPF (783M) vs DNLI (0).
DNLITLPPFDNLI / TLPPF
Capitalization2.16B3.02B72%
EBITDA-521.52M92.5M-564%
Gain YTD-24.289-39.63361%
P/E RatioN/A387.72-
Revenue0783M-
Total Cash899M710M127%
Total Debt46.6M581M8%
FUNDAMENTALS RATINGS
DNLI vs TLPPF: Fundamental Ratings
DNLI
TLPPF
OUTLOOK RATING
1..100
1158
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
10056
SMR RATING
1..100
9668
PRICE GROWTH RATING
1..100
6294
P/E GROWTH RATING
1..100
995
SEASONALITY SCORE
1..100
24n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (93) in the Biotechnology industry is in the same range as TLPPF (93) in the null industry. This means that DNLI’s stock grew similarly to TLPPF’s over the last 12 months.

TLPPF's Profit vs Risk Rating (56) in the null industry is somewhat better than the same rating for DNLI (100) in the Biotechnology industry. This means that TLPPF’s stock grew somewhat faster than DNLI’s over the last 12 months.

TLPPF's SMR Rating (68) in the null industry is in the same range as DNLI (96) in the Biotechnology industry. This means that TLPPF’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Price Growth Rating (62) in the Biotechnology industry is in the same range as TLPPF (94) in the null industry. This means that DNLI’s stock grew similarly to TLPPF’s over the last 12 months.

TLPPF's P/E Growth Rating (5) in the null industry is significantly better than the same rating for DNLI (99) in the Biotechnology industry. This means that TLPPF’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLITLPPF
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
67%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
68%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 11 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 5 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLPPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VGORX62.42N/A
N/A
Voya Large-Cap Growth R
ABSIX21.27N/A
N/A
AB Discovery Value I
FNKLX16.84N/A
N/A
Fidelity Series Value Discovery
GCPAX21.08N/A
N/A
Gateway Equity Call Premium A
CAPOX10.68N/A
N/A
Absolute Capital Opportunities Instl

TLPPF and

Correlation & Price change

A.I.dvisor tells us that TLPPF and GLMD have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TLPPF and GLMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLPPF
1D Price
Change %
TLPPF100%
-1.95%
GLMD - TLPPF
25%
Poorly correlated
+6.25%
DNLI - TLPPF
24%
Poorly correlated
+4.33%
BEAM - TLPPF
24%
Poorly correlated
+12.62%
RXRX - TLPPF
23%
Poorly correlated
+1.99%
JANX - TLPPF
23%
Poorly correlated
+0.17%
More